His Israeli replacement Erez Vigodman departed the company in February for undisclosed reasons amid a steep fall in the firm's share price and after a buyout binge that was criticized by investors. Mr. Vigodman's acquisition last year of Allergan PLC's generics unit -- Teva's biggest-ever deal -- left the company with debt of roughly $35 billion. It is attempting to pay down those borrowings with asset sales, but has so far found few takers for its businesses. In an effort to address investor concerns that its board lacked international pharmaceutical experience, Teva in June nominated four new directors and Mr. Schultz further addresses those concerns. At H. Lundbeck, he was credited with launching a turnaround, including job cuts and the restructuring of its business, which last year returned the firm to full-year profit. H.